• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向抑制 RBPJ 转录复合物可减轻肝癌中 CD8 T 细胞的耗竭。

Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8 T cells in hepatocellular carcinoma.

机构信息

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.

Cancer Center of Fujian Medical University, Fujian Medical University Union Hospital, Fuzhou, China.

出版信息

Commun Biol. 2023 Jan 30;6(1):123. doi: 10.1038/s42003-023-04521-x.

DOI:10.1038/s42003-023-04521-x
PMID:36717584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9887061/
Abstract

Impaired function of CD8 T cells in hepatocellular carcinoma (HCC) is an important reason for acquired resistance. Compared with single-target inhibitors, small-molecule compounds that could both inhibit tumor cells and alleviate T cell exhaustion are more promising to reduce resistance. In this study, we screened immunosuppressive targets in HCC by combining cancer-immunity cycle score with weighted gene co-expression network and system analysis. Through in vitro and in vivo validation experiments, we found that one of the screened molecules, recombination signal binding protein for immunoglobulin kappa J region (RBPJ), was negatively correlated with CD8 T cell mediated killing function. More importantly, its transcription complex inhibitor RIN1 not only inhibited the malignant biological behaviors of HCC cells by inhibiting mTOR pathway, but also reduced the expression of PD-L1 and L-kynurenine synthesis in HCC cells, thus alleviating T cell exhaustion. Meanwhile, the combination of RIN1 and anti-PD-1/PD-L1 antibodies could further activate CD8 T cells. In short, RBPJ is an important factor regulating the function of T cells. Target inhibition of RBPJ transcription complex by small molecule compound may be a new strategy for immunotherapy of HCC.

摘要

CD8 T 细胞在肝细胞癌(HCC)中的功能障碍是获得性耐药的一个重要原因。与单靶点抑制剂相比,既能抑制肿瘤细胞又能缓解 T 细胞衰竭的小分子化合物更有希望降低耐药性。在这项研究中,我们通过将癌症免疫周期评分与加权基因共表达网络和系统分析相结合,筛选出 HCC 中的免疫抑制靶点。通过体外和体内验证实验,我们发现筛选出的分子之一,重组信号结合蛋白免疫球蛋白 κJ 区(RBPJ)与 CD8 T 细胞介导的杀伤功能呈负相关。更重要的是,其转录复合物抑制剂 RIN1 不仅通过抑制 mTOR 通路抑制 HCC 细胞的恶性生物学行为,还降低 HCC 细胞中 PD-L1 和 L-犬尿氨酸合成的表达,从而缓解 T 细胞衰竭。同时,RIN1 与抗 PD-1/PD-L1 抗体的联合使用可以进一步激活 CD8 T 细胞。总之,RBPJ 是调节 T 细胞功能的重要因素。小分子化合物对 RBPJ 转录复合物的靶向抑制可能是 HCC 免疫治疗的一种新策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/62ec456af0ac/42003_2023_4521_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/2e43dac8f18c/42003_2023_4521_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/89885bd5b14e/42003_2023_4521_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/2928859d7acc/42003_2023_4521_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/5d82894db9dc/42003_2023_4521_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/f58f20e1e5d1/42003_2023_4521_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/8f0f7e54c198/42003_2023_4521_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/62ec456af0ac/42003_2023_4521_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/2e43dac8f18c/42003_2023_4521_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/89885bd5b14e/42003_2023_4521_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/2928859d7acc/42003_2023_4521_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/5d82894db9dc/42003_2023_4521_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/f58f20e1e5d1/42003_2023_4521_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/8f0f7e54c198/42003_2023_4521_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b008/9887061/62ec456af0ac/42003_2023_4521_Fig7_HTML.jpg

相似文献

1
Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8 T cells in hepatocellular carcinoma.靶向抑制 RBPJ 转录复合物可减轻肝癌中 CD8 T 细胞的耗竭。
Commun Biol. 2023 Jan 30;6(1):123. doi: 10.1038/s42003-023-04521-x.
2
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.SIRT7 缺失通过 MEF2D 调控程序性细胞死亡配体 1 增加肝癌细胞中检查点抑制剂的疗效。
Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31.
3
SRSF10 facilitates HCC growth and metastasis by suppressing CD8T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy.SRSF10 通过抑制 CD8T 细胞浸润促进 HCC 生长和转移,靶向 SRSF10 可增强抗 PD-L1 治疗效果。
Int Immunopharmacol. 2024 Jan 25;127:111376. doi: 10.1016/j.intimp.2023.111376. Epub 2023 Dec 18.
4
System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.基于癌症免疫循环的系统分析确定 ZNF207 为肝细胞癌的新型免疫治疗靶点。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004414.
5
Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.雄激素受体通过抑制肝癌中的 PD-L1 影响免疫检查点治疗的反应。
Aging (Albany NY). 2020 Jun 24;12(12):11466-11484. doi: 10.18632/aging.103231.
6
Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8 T cell activation to eradicate hepatocellular carcinoma.索拉非尼抑制放射抵抗并协同放射治疗介导的 CD8 T 细胞激活以根除肝细胞癌。
Int Immunopharmacol. 2022 Nov;112:109110. doi: 10.1016/j.intimp.2022.109110. Epub 2022 Aug 27.
7
Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.CMTM4 在肝细胞癌中的预后意义和免疫特征。
BMC Cancer. 2022 Aug 19;22(1):905. doi: 10.1186/s12885-022-09999-y.
8
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.针对免疫检查点分子的抗体恢复了肝癌浸润 T 细胞的功能。
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
9
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.针对索拉非尼获得性耐药的人肝癌中 PD-L1/DNMT1 轴。
Oncol Rep. 2017 Aug;38(2):899-907. doi: 10.3892/or.2017.5722. Epub 2017 Jun 14.
10
Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.库普弗细胞对人肝细胞癌中CD8 + T细胞的抑制作用是由B7-H1/程序性死亡-1相互作用介导的。
Cancer Res. 2009 Oct 15;69(20):8067-75. doi: 10.1158/0008-5472.CAN-09-0901. Epub 2009 Oct 13.

引用本文的文献

1
N-glycosylated LTβR increases the Th17/Treg cell ratio in liver cancer by blocking RORC ubiquitination and FOXP3 transcription.N-糖基化的LTβR通过阻断RORC泛素化和FOXP3转录来增加肝癌中Th17/Treg细胞比例。
Cell Death Dis. 2025 May 28;16(1):421. doi: 10.1038/s41419-025-07738-2.
2
Short-term starvation inhibits CD36 N-glycosylation and downregulates USP7 UFMylation to alleviate RBPJ-maintained T cell exhaustion in liver cancer.短期饥饿抑制CD36的N-糖基化并下调USP7的UFMylation,以减轻RBPJ维持的肝癌T细胞耗竭。
Theranostics. 2025 Apr 28;15(12):5931-5952. doi: 10.7150/thno.110567. eCollection 2025.
3

本文引用的文献

1
Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.脂多糖通过对长链非编码RNA MIR155HG进行m6A修饰以上调PD-L1表达,从而促进肝癌细胞的免疫逃逸。
Cell Biol Toxicol. 2022 Dec;38(6):1159-1173. doi: 10.1007/s10565-022-09718-0. Epub 2022 Apr 19.
2
Analysis of Gene Co-Expression Network to Identify the Role of CD8 + T Cell Infiltration-Related Biomarkers in High-Grade Glioma.基因共表达网络分析以确定CD8 + T细胞浸润相关生物标志物在高级别胶质瘤中的作用
Int J Gen Med. 2022 Feb 22;15:1879-1890. doi: 10.2147/IJGM.S348470. eCollection 2022.
3
Prediction model for the early recurrence of stage IA-IIA non-small cell lung cancer based on hematological indexes and imaging features.
基于血液学指标和影像学特征的IA-IIA期非小细胞肺癌早期复发预测模型
Discov Oncol. 2025 May 7;16(1):684. doi: 10.1007/s12672-025-02514-2.
4
Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies.解析肿瘤微环境中的T细胞耗竭:为创新实体瘤疗法铺平道路。
Front Immunol. 2025 Apr 1;16:1548234. doi: 10.3389/fimmu.2025.1548234. eCollection 2025.
5
Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma.肿瘤微环境在肝细胞癌免疫检查点阻断治疗耐药中的复杂作用。
Cancer Drug Resist. 2025 Feb 26;8:10. doi: 10.20517/cdr.2024.165. eCollection 2025.
6
Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunity.单细胞转录组学和表观基因组学表明,CD58-CD2相互作用在控制原发性黑色素瘤生长和免疫方面发挥作用。
Cancer Commun (Lond). 2025 Apr;45(4):465-470. doi: 10.1002/cac2.12651. Epub 2025 Jan 15.
7
Integrating Single-Cell RNA-Seq and Bulk RNA-Seq to Construct a Novel γδT Cell-Related Prognostic Signature for Human Papillomavirus-Infected Cervical Cancer.整合单细胞 RNA-Seq 和批量 RNA-Seq 构建新型人乳头瘤病毒感染宫颈癌 γδT 细胞相关预后标志物。
Cancer Control. 2024 Jan-Dec;31:10732748241274228. doi: 10.1177/10732748241274228.
8
Harnessing CD8 T cell dynamics in hepatitis B virus-associated liver diseases: Insights, therapies and future directions.利用乙型肝炎病毒相关肝脏疾病中的 CD8 T 细胞动力学:见解、疗法和未来方向。
Clin Transl Med. 2024 Jul;14(7):e1731. doi: 10.1002/ctm2.1731.
9
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Notch 信号通路与癌症:从机制研究到靶向治疗。
Signal Transduct Target Ther. 2024 May 27;9(1):128. doi: 10.1038/s41392-024-01828-x.
10
New insights into T-cell exhaustion in liver cancer: from mechanism to therapy.肝癌中 T 细胞耗竭的新见解:从机制到治疗。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12543-12560. doi: 10.1007/s00432-023-05083-5. Epub 2023 Jul 9.
Interleukin-10 receptor signaling promotes the maintenance of a PD-1 TCF-1 CD8 T cell population that sustains anti-tumor immunity.
白细胞介素-10 受体信号促进 PD-1 TCF-1 CD8 T 细胞群体的维持,从而维持抗肿瘤免疫。
Immunity. 2021 Dec 14;54(12):2825-2841.e10. doi: 10.1016/j.immuni.2021.11.004. Epub 2021 Dec 7.
4
Tpt1 the balance toward immunosuppression upon cell death.Tpt1在细胞死亡时使平衡趋向免疫抑制。
Nat Immunol. 2021 Aug;22(8):940-942. doi: 10.1038/s41590-021-00986-2.
5
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.髓源性抑制细胞在癌症和免疫治疗中的免疫抑制作用。
Cells. 2021 May 11;10(5):1170. doi: 10.3390/cells10051170.
6
Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.通过 Notch-c-Myc-EZH2 致癌信号通路的基质触发来控制 CLL 细胞中的 PD-L1 表达。
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-001889.
7
A snapshot of the PD-1/PD-L1 pathway.PD-1/PD-L1 通路示意图
J Cancer. 2021 Mar 5;12(9):2735-2746. doi: 10.7150/jca.57334. eCollection 2021.
8
Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8 T cell immunity.肠道微生物代谢物通过调节细胞毒性 CD8 T 细胞免疫来促进癌症治疗疗效。
Cell Metab. 2021 May 4;33(5):988-1000.e7. doi: 10.1016/j.cmet.2021.03.002. Epub 2021 Mar 23.
9
Gut Microbiota in Cancer Immune Response and Immunotherapy.肠道微生物群在癌症免疫反应和免疫治疗中的作用。
Trends Cancer. 2021 Jul;7(7):647-660. doi: 10.1016/j.trecan.2021.01.010. Epub 2021 Mar 2.
10
Transcription Factor RBPJ as a Molecular Switch in Regulating the Notch Response.转录因子 RBPJ 作为调节 Notch 反应的分子开关。
Adv Exp Med Biol. 2021;1287:9-30. doi: 10.1007/978-3-030-55031-8_2.